Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology... see more

TSX:CPH - Post Discussion

View:
Post by r0nald on Nov 13, 2020 9:25am

Tax Losses

Did I hear that correctly? Will the tax losses of, what was it $100 million (?), be used by end of 2020(!). They are in talks about that? What should that be worth $10-20 million? Amazing!
Comment by alfhope on Nov 13, 2020 4:38pm
Where do you see tax losses of $ 100 million ? Dont understand.
Comment by r0nald on Nov 13, 2020 5:37pm
That is the number I recalled. I was wrong though, factually it something like $ 210 million. "The Company has various non-capital losses of approximately $210 million and proactively works with its tax advisors to utilize these losses with the objective of minimizing the amount of cash taxes payable."  https://filecache.investorroom.com/mr5ircnw_cipher/229/download/Q1%202020 ...more  
Comment by nozzpack on Nov 13, 2020 7:09pm
The Cardiome subsidiary has non-capital losses of $211,390,000 ,investment tax credits of $13,587,000  and SR&ED expenditures of $54,859,00  The non-capital losses expire in varying amounts from 2026 to 2036. The investment tax credits expire in varying amounts from 2023 to 2032.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities